DK2299977T3 - Liposomer til lægemiddelafgivelse og fremgangsmåder til fremstilling heraf - Google Patents

Liposomer til lægemiddelafgivelse og fremgangsmåder til fremstilling heraf

Info

Publication number
DK2299977T3
DK2299977T3 DK09749940.4T DK09749940T DK2299977T3 DK 2299977 T3 DK2299977 T3 DK 2299977T3 DK 09749940 T DK09749940 T DK 09749940T DK 2299977 T3 DK2299977 T3 DK 2299977T3
Authority
DK
Denmark
Prior art keywords
liposomes
processes
preparation
drug delivery
drug
Prior art date
Application number
DK09749940.4T
Other languages
English (en)
Inventor
Anders Falk Vikbjerg
Fredrik Melander
Jonas Rosager Henriksen
Sune Allan Petersen
Kent Joergensen
Original Assignee
Liplasome Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liplasome Pharma Aps filed Critical Liplasome Pharma Aps
Application granted granted Critical
Publication of DK2299977T3 publication Critical patent/DK2299977T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK09749940.4T 2008-05-23 2009-05-25 Liposomer til lægemiddelafgivelse og fremgangsmåder til fremstilling heraf DK2299977T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200800717 2008-05-23
EP08014793A EP2123258A1 (en) 2008-05-23 2008-08-20 Liposomes for drug delivery
PCT/EP2009/056297 WO2009141450A2 (en) 2008-05-23 2009-05-25 Liposomes for drug delivery and methods for preparation thereof

Publications (1)

Publication Number Publication Date
DK2299977T3 true DK2299977T3 (da) 2012-11-05

Family

ID=40221427

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09749940.4T DK2299977T3 (da) 2008-05-23 2009-05-25 Liposomer til lægemiddelafgivelse og fremgangsmåder til fremstilling heraf

Country Status (14)

Country Link
US (2) US20120009243A1 (da)
EP (2) EP2123258A1 (da)
JP (1) JP5767580B2 (da)
CN (1) CN102065840B (da)
AU (1) AU2009248673B2 (da)
CA (1) CA2725529C (da)
CY (1) CY1115325T1 (da)
DK (1) DK2299977T3 (da)
ES (1) ES2393170T3 (da)
HR (1) HRP20120776T1 (da)
PL (1) PL2299977T3 (da)
PT (1) PT2299977E (da)
SI (1) SI2299977T1 (da)
WO (1) WO2009141450A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) * 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
CA2848173C (en) * 2011-05-10 2019-07-02 The Penn State Research Foundation Ceramide anionic liposome compositions
CN102579350B (zh) * 2012-03-02 2013-04-24 海南灵康制药有限公司 右旋布洛芬脂质体固体制剂
EP2883542B1 (en) * 2012-08-10 2019-05-01 Taiho Pharmaceutical Co., Ltd. Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
MA37931A1 (fr) * 2012-08-13 2016-07-29 Teni Boulikas Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite
CN103169659A (zh) * 2012-11-23 2013-06-26 杭州师范大学 一种奥沙利铂长循环脂质体及其应用
WO2014160438A1 (en) * 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
KR101683635B1 (ko) * 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
CN104758250B (zh) * 2015-03-04 2021-06-01 王海龙 一种紫杉醇脂质体及其制备方法和用途
US10688199B2 (en) * 2015-06-10 2020-06-23 Teikyo University Theranostic bubble preparation (TB), and method for using same
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
WO2018195292A1 (en) 2017-04-19 2018-10-25 Mayo Foundation For Medical Education And Research Ketamine and propofol admixture
US11590079B2 (en) 2018-01-18 2023-02-28 EndoProtech, Inc. Treating microvascular dysfunction
AU2019200325A1 (en) * 2018-01-31 2019-08-15 Liplasome Pharma Aps Methods for treating cancer and predicting drug responsiveness in cancer patients
CN110522728B (zh) * 2019-10-11 2022-03-15 上海市同仁医院 一种介孔二氧化硅纳米递药系统、制备方法及其应用
US20230285292A1 (en) * 2020-06-23 2023-09-14 The Trustees Of The University Of Pennsylvania Compositions and methods of using a pla2-responsive drug delivery system

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) * 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
IL93996A0 (en) * 1989-04-04 1991-01-31 Alcon Lab Inc Pharmaceutical composition containing a liposome
US5227170A (en) * 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US6027726A (en) 1994-09-30 2000-02-22 Inex Phamaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
AU2284697A (en) * 1996-04-11 1997-10-29 University Of British Columbia, The Fusogenic liposomes
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
AU1656799A (en) 1997-12-12 1999-07-05 Inex Pharmaceuticals Corp. Cationic drugs encapsulated in anionic liposomes
US6911306B1 (en) 1999-10-18 2005-06-28 Emory University TMS1 compositions and methods of use
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
AU778659B2 (en) 2000-02-10 2004-12-16 Liplasome Pharma A/S Lipid-based drug delivery systems
EP1839670A3 (en) * 2001-02-21 2009-11-11 Alavita Pharmaceuticals, Inc. Modified Annexin Proteins and their use against thrombosis
US20030026831A1 (en) * 2001-04-20 2003-02-06 Aparna Lakkaraju Anionic liposomes for delivery of bioactive agents
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
WO2003041682A2 (en) * 2001-11-13 2003-05-22 Celator Technologies, Inc. Lipid carrier compositions and methods for improved drug retention
US8518437B2 (en) 2001-11-13 2013-08-27 Celator Pharmaceuticals, Inc. Lipid carrier compositions with enhanced blood stability
US7273620B1 (en) 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
US20040018525A1 (en) 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
CA2490959C (en) 2002-07-02 2013-04-16 Board Of Regents, The University Of Texas System Radiolabeled compounds and liposomes and their methods of making and using the same
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
US20040203069A1 (en) * 2003-04-10 2004-10-14 Chris Reutelingsperger Method for determining and/or isolating lipid-binding compounds
WO2004098524A2 (en) * 2003-05-02 2004-11-18 Aronex Pharmaceuticals, Inc. Lipid platinum complexes and methods of use thereof
WO2005000266A2 (en) * 2003-05-22 2005-01-06 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
WO2005000272A1 (en) * 2003-06-04 2005-01-06 Isis Pharmaceuticals, Inc. Long-circulating liposomal compositions
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1547674A1 (en) 2003-12-23 2005-06-29 MediGene Oncology GmbH Method for producing colloidal nanoparticles
CA2554818A1 (en) 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
CN107811971B (zh) 2004-05-03 2021-10-29 益普生生物制药公司 用于药物输送的脂质体
EP1795182A4 (en) 2004-08-31 2012-10-03 Astellas Pharma Inc LIPOSOME IMPROVING INTRACELLULAR DRUG DELIVERY
EP1838283B1 (en) 2004-11-03 2008-12-31 Liplasome Pharma A/S Lipid-based drug delivery systems containing unnatural phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof
PE20070360A1 (es) * 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
AU2006306108B2 (en) 2005-10-25 2012-10-04 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
ES2527592T3 (es) 2006-01-05 2015-01-27 The Ohio State University Research Foundation Métodos basados en microARN para el diagnóstico del cáncer de colon
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
WO2007123691A2 (en) * 2006-03-30 2007-11-01 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
JP5248492B2 (ja) * 2006-07-14 2013-07-31 エフエムシー バイオポリマー エイエス 低分子量アルギネートを含むヒドロゲルおよびそれから製造されたバイオ構造物
US20080069778A1 (en) * 2006-09-20 2008-03-20 Imarx Therapeutics, Inc. Polymer-encapsulated microspheres
US20090162425A1 (en) 2007-09-19 2009-06-25 University Of Tennessee Research Foundation Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients

Also Published As

Publication number Publication date
AU2009248673A1 (en) 2009-11-26
SI2299977T1 (sl) 2012-11-30
CA2725529A1 (en) 2009-11-26
US20200171080A1 (en) 2020-06-04
US20120009243A1 (en) 2012-01-12
EP2299977A2 (en) 2011-03-30
CA2725529C (en) 2016-07-05
CN102065840B (zh) 2014-12-10
EP2123258A1 (en) 2009-11-25
JP5767580B2 (ja) 2015-08-19
WO2009141450A2 (en) 2009-11-26
WO2009141450A3 (en) 2010-07-08
EP2299977B1 (en) 2012-08-15
PL2299977T3 (pl) 2013-01-31
US11173178B2 (en) 2021-11-16
CY1115325T1 (el) 2017-01-04
CN102065840A (zh) 2011-05-18
HRP20120776T1 (hr) 2012-10-31
ES2393170T3 (es) 2012-12-19
AU2009248673B2 (en) 2014-08-21
JP2011521913A (ja) 2011-07-28
PT2299977E (pt) 2012-09-07

Similar Documents

Publication Publication Date Title
DK2299977T3 (da) Liposomer til lægemiddelafgivelse og fremgangsmåder til fremstilling heraf
BRPI0912918A2 (pt) aparelho de aplicação de fármaco respiratório
DK2296732T3 (da) Medikamentafgivelsesindretning
DK2398500T3 (da) Glutathion-baseret lægemiddelafgivelsessystem
DK2414011T3 (da) Medikamentafgivelsesindretning
DK2185220T3 (da) Anordning til lægemiddelfremføring
DK2274030T4 (da) Lægemiddelafgivelsesanordning
DK2493532T3 (da) Lægemiddelfremføringsanordning
ZA201101737B (en) Progestin-containing drug delivery system
IL213376A0 (en) Zaleplon gastroretentive drug delivery system and uses thereof
IL210883A0 (en) Drug delivery system and method of munufacturing thereof
EP2299989A4 (en) STABILIZED TRANSDERMAL DRUG DISPENSING SYSTEM
ATE531410T1 (de) Arzneimittelabgabevorrichtung
DK2403569T3 (da) Lægemiddelafgivelsesanordning med tilbagetrækkelig nål
DK2437830T3 (da) Anordning til lægemiddelleveringsindretning og lægemiddelleveringsindretning
DK2493531T4 (da) Lægemiddelfremføringsindretninger og fremgangsmåde til samling
DK2355867T3 (da) Anordning til medikamentafgivelse
BRPI1005433A2 (pt) preparações farmacêuticas transdérmicas
DK2437736T3 (da) Lægemiddelindgivelsessystemer
IL212357A0 (en) Sustained drug delivery system
IL213577A0 (en) Drug delivery device
DK2301611T3 (da) Lægemiddelafgivelsesindretning
ZA201109514B (en) Method of drug delivery
DK2341900T3 (da) Lægemiddelprodukt og behandling
IL212603A0 (en) Combined drug administration